Rimidi Expands Team by 86%, Grows Revenue by 100% in First Half of 2022

Strategic hires and overarching company growth showcases Rimidi’s commitment to helping clinicians optimize data to enable better clinical workflows and improve outcomes

ATLANTA – July 6, 2022 -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, announced today that the company has expanded its employee base by 86% and seen a 100% growth in revenue, accompanied by an enlargement of its Atlanta headquarters. The overarching company growth and momentum further underscores Rimidi’s commitment and ability to create innovative solutions for its hospital, health system, and provider customers that result in better workflows, experiences, and outcomes.

Rimidi continues to be a leader in enterprise software for chronic disease management and clinical workflow optimization, including remote patient monitoring and clinical decision support. Recent additions to the team will further support the company in developing a sustainable product roadmap and a secure, scalable software platform.

“As we continue to grow our client base to larger health systems and Integrated Delivery Networks, our focus remains on optimizing data for clinicians in their workflow,” said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. “Our employee growth across quality, compliance, product and client success is pivotal to achieving this goal.”

Additionally, in an effort to further bring innovation to Rimidi customers, the company recently announced partnerships with ARKRAY’s GLUCOCARD® Shine Connex Blood Glucose Monitoring System and Abbott’s FreeStyle Libre Continuous Glucose Monitoring system. The two devices are now part of an ecosystem of cellular and Bluetooth-enabled devices that integrate with the Rimidi platform, enabling clinicians to view data from a breadth of different connected devices in one unified platform, in their existing workflow, and in the context of other relevant patient data.

Rimidi also recently became a Business Partner of the National Association of Accountable Care Organizations (NAACOS), which works on behalf of health systems and physician provider organizations across the nation participating in population health-focused payment models to improve quality of care, outcomes, and healthcare cost efficiency. With this partnership, Rimidi will actively engage with ACO leaders and CMS officials to exchange ideas, share best practices, and ensure that Rimidi’s products continue to support the goals of value-based healthcare.

Additional 2022 Rimidi milestones include:

• Recognized as a Top 5 Company in Remote Monitoring upon conclusion of extensive research and company outreach by AVIA Connect, the leading digital health marketplace
• Showcased Rimidi's latest medical device integrations, including its integration with Abbott’s FreeStyle Libre continuous glucose monitoring system, and industry-leading implementation of CDS Hooks for clinical decision support at ViVE and HIMSS.
• Dr. Ide presented at the Modern Healthcare Transformation Summit as part of a panel on "The Path From Startup to Scaleup," and spoke at the California Health Information Association's premier event, CHIACON2022 on the topic of SMART on FHIR, interoperability and the 21st Century Cures Act and Final Rule.

Heading into the second half of 2022, Rimidi has additional product and technology developments planned, including new disease modules, device integrations, and EHR partners.

For more information on Rimidi, its solutions, and to stay abreast of upcoming news and updates, visit www.rimidi.com and follow the company on Twitter @JointheRimidi.